Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211407 | 0.82 | ITGB3 (0.52) | — | |
| Acetic Acid SCHEMBL7216501 | 0.81 | KMT2A (0.42) | ALDH1A1CTSLGAA | |
| SCHEMBL7217839 | 0.79 | ITGB3 (0.48) | ALDH1A1 | |
| SCHEMBL7960953 | 0.76 | CTSL (0.43) | CTSLCTSSCTSBCTSK | |
| SCHEMBL11373846 | 0.73 | ITGB3 (0.58) | CTSLCTSSCTSBCTSK | |
| SCHEMBL7983192 | 0.73 | ITGB3 (0.58) | — | |
| SCHEMBL7983179 | 0.73 | ITGB3 (0.58) | — | |
| SCHEMBL18920606 | 0.73 | TACR1 (0.66) | CTSLCTSSCTSBCTSK | |
| SCHEMBL8438830 | 0.73 | TACR1 (0.66) | CTSLCTSSCTSBCTSK | |
| SCHEMBL8234111 | 0.73 | TACR1 (0.66) | CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| EP-0796855-A1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ALDH1A1 4551/4885CTSL 761/4885CTSS 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.